Medical Cannabis Regulatory Update – Towards Removal of CBD from the Israeli Dangerous Drugs Ordinance
Earlier this week, the Minister of Health adopted the conclusions, of the committee intended to examine the possibility of excluding CBD from the Israeli Dangerous Drugs Ordinance [New Version], 5737-1973 (the “Committee” and the “Ordinance”, respectively), and published a draft order, excluding CBD from the Ordinance (the “Order”), so that CBD (or any structural derivative of CBD) shall not be considered as a “dangerous drug” under the Ordinance, if the aggregate concentration of THC (or any structural derivative of THC) in it does not exceed 0.3%. The Order is open for public comments until March 22, 2022.
In the Committee’s conclusions and recommendations, which were published in February 2022,it was recommended to exclude CBD from the Ordinance, and to allow CBD use, other than in food and cosmetics products, provided that the aggregate concentration of THC do not exceed 0.2%. The Committee further recommended that during the next two years CBD components will not be approved as a component in food, food-supplements and cosmetics, and that this issue will be re-examined by a committee designated by the Ministry of Health.
The Committee further noted, that (i) research in the field of CBD products’ safety should be encouraged and budgeted; and (ii) laboratory recognition systems and a supervisory/enforcement system for the cosmetics and food fields should be established.
We note that the above is merely a short summary of the subject matter, and does not cover all relevant provisions of the guidelines.
For additional information please contact your Gross & Co. attorney or one of the following Adv. Hili Cohen, partner and head of life sciences department (Hili@gkh-law.com) Adv. Tami Fishman, partner (Tamif@gkh-law.com), or Adv. Ofir Goldstein (Ofirg@gkh-law.com).
